Stelara 90MG/ML SYR 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTGL
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $165,841
Award facts
- Contract value 100% obligated
- $165,841.30 Current and potential, with all options
- Completion date
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $165,841.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90mg/mL syringes. This delivery order, awarded on January 9, 2026, with an ultimate completion date of the same day, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was made without a set-aside, reflecting DMS Pharmaceutical Group's ability to compete effectively against other vendors for critical pharmaceutical supplies needed by Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. As a critical pharmaceutical supplier for Department of Defense healthcare operations worldwide, DMS Pharmaceutical Group has demonstrated substantial performance capability across diverse and specialized pharmaceutical product categories, including specialty biologics such as Stelara, supporting the recurring medical supply needs of military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FBTGL?
SPE2DR26FBTGL was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FBTGL worth?
The government has obligated $165,841 on SPE2DR26FBTGL.
Is contract SPE2DR26FBTGL an order under another contract?
Yes. SPE2DR26FBTGL is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTGL competed?
The extent of competition for SPE2DR26FBTGL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award